<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793962</url>
  </required_header>
  <id_info>
    <org_study_id>LC2008A06</org_study_id>
    <nct_id>NCT00793962</nct_id>
  </id_info>
  <brief_title>A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer</brief_title>
  <official_title>A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and toxicities of hypofractionation&#xD;
      radiotherapy with conventional fractionation radiotherapy in breast cancer patients treated&#xD;
      with mastectomy.It is hypothesized that the efficacy and toxicities are similar between the&#xD;
      two groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible breast cancer patients with mastectomy and axillary dissection are randomized into 2&#xD;
      groups:conventional fractionation radiotherapy of 50 Gy in 25 fractions within 5 weeks to&#xD;
      ipsilateral chest wall and supraclavicular nodal region,and hypofractionation radiotherapy of&#xD;
      43.5Gy in 15 fractions within 3 weeks to the same region.&#xD;
&#xD;
      During and after radiotherapy, the patients are followed and the efficacy and toxicities of&#xD;
      radiotherapy are evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>locoregional control rate</measure>
    <time_frame>5 years</time_frame>
    <description>ipsilateral chest wall, axilla, supraclavicular and internal mammary nodal relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>any death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">810</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>hypofractionation radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional fractionation radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionation radiotherapy</intervention_name>
    <description>radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region</description>
    <arm_group_label>hypofractionation radiotherapy</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conventional fractionation radiotherapy</intervention_name>
    <description>50Gy/25/f/5w</description>
    <arm_group_label>conventional fractionation radiotherapy</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ipsilateral histologically confirmed invasive breast cancer&#xD;
&#xD;
          -  Undergone total mastectomy and axillary dissection&#xD;
&#xD;
          -  T3-4,or &gt;=4 positive axillary lymph nodes&#xD;
&#xD;
          -  Fit for chemotherapy(if indicated),endocrine therapy(if indicated)and postoperative&#xD;
             irradiation&#xD;
&#xD;
          -  Written,informed consent&#xD;
&#xD;
          -  cT3-4,or cN2, or pathological positive axillary lymph nodes during mastectomy for&#xD;
             patients who had received neoadjuvant chemotherapy or hormone therapy&#xD;
&#xD;
          -  no supraclavicular or internal mammary nodes metastases&#xD;
&#xD;
          -  no distant metastases&#xD;
&#xD;
          -  enrollment date no more than 8 months after surgery or no more than 2 months after&#xD;
             chemotherapy for patients who didn't receive neoadjuvant systemic therapy.&#xD;
&#xD;
          -  enrollment date no more than 2 months after surgery for patients who had received&#xD;
             neoadjuvant systemic therapy and didn't need adjuvant chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who undergone previous irradiation to the ipsilateral chest wall and&#xD;
             supraclavicular region&#xD;
&#xD;
          -  Previous or concurrent malignant other than non-melanomatous skin cancer&#xD;
&#xD;
          -  Unable or unwilling to give informed consent&#xD;
&#xD;
          -  bilateral breast cancer&#xD;
&#xD;
          -  immediate or delayed ipsilateral breast cancer reconstruction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shu-lian wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ye-xiong Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shu lian Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>mastectomy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>fractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

